Histamine H 3 receptors (H 3 R) are widely expressed in the brain where they participate in sleep-wake cycle and cognition among other functions. Despite their high expression in some regions of the basal ganglia, their functional role in this forebrain neural network remains unclear. The present findings provide in situ hybridization and immunohistochemical evidence for H 3 R expression in several neuronal populations of the rat basal ganglia but not in astrocytes (glial fibrillary acidic protein immunoreactive cells). We demonstrate the presence of H 3 R mRNA and protein in dopaminergic neurons (tyrosine hydroxylase positive) of the ventral tegmental area and substantia nigra. In the dorsal and ventral (nucleus accumbens) striatal complex we show H 3 R immunoreactivity in cholinergic (choline acetyltransferase immunoreactive) and GABAergic neurons (substance P, proenkephalin or dopamine D 1 receptor positive) as well as in corticostriatal terminals (VGLUT1-immunoreactive). Double-labelling experiments in the medial prefrontal cortex show that H 3 R is expressed in D 1 R-positive interneurons and VGLUT1-positive corticostriatal output neurons. Our functional experiments confirm that H 3 R ligands modulate dopamine synthesis and the probability of glutamate release in the striatum from cortico-striatal afferents. The presence of H 3 R in such different neuronal populations and its involvement in the control of striatal dopaminergic and glutamatergic transmission ascribes a complex role to H 3 R in the function of the basal ganglia neural network.
Abstract:
Histamine H 3 receptors (H 3 R) are widely expressed in the brain where they participate in sleep-wake cycle and cognition among other functions. Despite their high expression in some regions of the basal ganglia, their functional role in this forebrain neural network remains unclear. The present findings provide in situ hybridization and immunohistochemical evidence for H 3 R expression in several neuronal populations of the rat basal ganglia but not in astrocytes (glial fibrillary acidic protein immunoreactive cells). We demonstrate the presence of H 3 R mRNA and protein in dopaminergic neurons (tyrosine hydroxylase positive) of the ventral tegmental area and substantia nigra. In the dorsal and ventral (nucleus accumbens) striatal complex we show H 3 R immunoreactivity in cholinergic (choline acetyltransferase immunoreactive) and GABAergic neurons (substance P, proenkephalin or dopamine D 1 receptor positive) as well as in corticostriatal terminals (VGLUT1-immunoreactive). Double-labelling experiments in the medial prefrontal cortex show that H 3 R is expressed in D 1 R-positive interneurons and VGLUT1-positive corticostriatal output neurons. Our functional experiments confirm that H 3 R ligands modulate dopamine synthesis and the probability of glutamate release in the striatum from cortico-striatal afferents. The presence of H 3 R in such different neuronal populations and its involvement in the control of striatal dopaminergic and glutamatergic transmission ascribes a complex role to H 3 R in the function of the basal ganglia neural network.
Introduction
Histamine is involved in a variety of brain functions such as the sleep-wake cycle, attention, learning, memory and the control of food intake and locomotion [1, 2] through its interaction with four identified G-protein coupled receptors. Three of them (H 1 to H 3 ) are widely distributed in the central nervous system while the H 4 receptor is expressed mostly in bone marrow and leukocytes, displaying very low levels in brain [3, 4] .
The histamine H 3 receptor (H 3 R) was initially described as an autoreceptor controlling histamine release and synthesis in histaminergic terminals of the central nervous system [5, 6] . Later, its heteroreceptor role was demonstrated as it also modulates the release of other neurotransmitters including serotonin [7] , norepinephrine [8] , dopamine [9] , glutamate [10] and GABA [11] in brain samples. Many human and rat H 3 R mRNA isoforms are generated by differential splicing [12] . In the rat, four isoforms are functionally active: H 3(445), H 3(413), H 3(410), H 3(397) . H 3(413) has been suggested to be the autoreceptor of histaminergic neurons [13] . The H 3 R isoforms have a heterogenous expression level in cerebral structures [14] being highly expressed in cortex, thalamus and caudate-putamen [15] . This regional localisation matches the relative distribution of histaminergic projections arising from the tuberomammillary nucleus. In addition, radioligand binding studies in rodents show high H 3 R levels in olfactory nucleus, cortex, substantia nigra pars reticulata (SNr), amygdala, thalamus and hypothalamus, specially in tuberomammillary nucleus, with the highest density in striatum and nucleus accumbens [16] .
The rat striatum is the main input structure of the basal ganglia involved in sensory-motor behavioural coordination. It can be divided in dorsal and ventral regions: Dorsal striatum (caudate-putamen) has been implicated in the initiation and development of a voluntary motor behaviour, while the ventral striatum (nucleus accumbens, Acb) plays a central role in motivated and goal directed behaviours because it integrates information from motor and limbic systems [17] . Dorsal and ventral striatum differ in afferences and efferences, but both present the same neuronal phenotypes. Thus 95% of striatal neurons are GABAergic spiny projection neurons, which can be divided in two populations: striato-nigral pathway neurons which show dynorphin, substance P (SP) and D 1 -like dopamine receptors and striato-pallidal pathway neurons that coexpress enkephalin and the D 2 -like dopamine receptor [18, 19] . Nevertheless, discrimination between these two populations is not absolutely clear because all of these neurons can express low levels of characteristic receptors of the other neuronal type [20, see also 21] . The remaining 5% of striatal neurons is composed by interneurons of two subtypes: cholinergic and GABAergic [22] .
Striatal neurons are a major target of mesencephalic dopaminergic neurons, which are implicated in complex neurological and psychiatric disorders such as Parkinson, Huntington, schizophrenia and addiction. The role of H 3 R in normal striatal functions such as locomotion control is not clearly elucidated [23, 24] , and even less in pathological conditions. However, the therapeutic potential of H 3 R antagonists is being studied in sleep-wake disorders, dementia, attention-deficit hyperactivity disorders, and schizophrenia [25, 26] . Conversely, stimulation of H 3 R decreases L-dopa-induced chorea and turning behaviour in animal models of Parkinson's disease [27, 28] . In the present work functional histamine H 3 R expression in basal ganglia neuronal populations is studied to evaluate the possibility that H 3 receptors constitute new targets for treatments of these disorders. Brain sections were incubated at 37ºC for 10 min with proteinase K (5µg/ml), acetylated for 10 min (in 0.1M triethanolamine, pH 8 and 0.25% acetic anhydride) at room temperature and dehydrated in graded ethanol up to 100%. Hybridization was performed overnight at 55ºC in the presence of 10-20 ng of biotin/digoxigenine labelled antisense or sense probes in hybridization buffer (50% formamide, 10% dextran sulfate, standard saline citrate 2x (SSC), 1% Denhart's solution, 50mM Tris-HCl buffer, 0.1% NaPPi, 0.2mg/ml tRNA, 1mM EDTA). Subsequently, sections were rinsed with: 50% formamide in SSC2x (30 min at 55ºC), SSC2x (5 min at 55ºC, 2 times 10 min at room temperature) and incubated for 40 min at 37ºC with ribonuclease. Then, sections were washed in graded SSC (4x and 2x, 15min each, 0.1x 30 min at 60ºC and 0.1x 10 min room temperature), Tris buffered saline 50mM pH 7.6 (TBS) -Tween 20 0.05% three times (5 min each) and blocked with 1% blocking reagent (Roche Applied Science) in TBS for 1 h at 37ºC. They were then incubated for 2 h at room temperature in a humid chamber with the primary antibodies sheep antidigoxigenine-peroxidase (Roche Applied Science, 1/100) and mouse anti-Biotin (Jackson Immunoresearch, 1/200) diluted in buffer (TBS, 0.1% acetylated bovine serum albumin, 1% goat serum, 0.1% Tween 20) . After three rinses with TBS-Tween 20 0.05% (5 min each) sections were incubated with the green secondary antibody anti-mouseAlexa488 (Invitrogen, 1/200) diluted in TBSTween 20 0.1% for 2 h at room temperature. Two more washes followed by one in TBS without Tween 20 (5 min) were performed before the incubation with the red fluorophore, which is conjugated to tyramide signal amplification (TSA)-Cy3 activated by peroxidase (Perkin Elmer, 1/500). Finally, sections were washed and mounted with Mowiol.
Experimental procedures
The H 3 R probe corresponded to nucleotides 636-1243 of the rat H 3 R sequence. It was previously shown to hybridize to the various H 3 R mRNA isoforms expressed in the brain or peripheral tissues [14, 16] . The tyrosine hydroxylase probe used to detect dopaminergic neurons was complementary to rat tyrosine hydroxylase mRNA sequence from nucleotide 25 till the end. cDNAs for proenkephalin (PE) and SP were obtained by polymerase chain reaction and corresponded to nucleotides 335-641 (GenBank accession n° AH002996) and nucleotides 80 -227 (AH002233), respectively. They were subcloned into pGEM-4Z (Promega) plasmids. Antisense and sense cRNA riboprobes were prepared by in vitro transcription. The sense probe was used as a control for the specificity of the signal obtained with the antisense probe.
Fluorescent immunohistochemistry
Brain sections were thawed at 4ºC, washed in TBS for 5 min, then in sodium borohydrate 1% (diluted in disodium hydrogenphosphate 0.1M pH 7.8) for 20 min and rinsed in phosphate buffer saline 50mM pH 7.4 and TBS (3 min each). Blocking was made with 7% donkey serum in TBS for 1 h at 37ºC. Primary antibodies (listed in Table 1 ) were diluted in buffer (TBS, acetylated bovine serum albumin 1%, Tween 20 0.1%, 7% donkey serum) and incubated overnight at 4ºC. Histamine H 3 receptor expression in dopaminergic and cholinergic neurons was detected using the Abcam antibody while the Alpha Diagnostic H3R31A antibody was employed for the other experiments as they showed similar immunostaining (Fig. 3) . The H 3 R signal specificity was tested by comparing three different commercial antibodies and by blocking Alpha Diagnostic anti-H 3 (H 3 Ral) signal with its blocking peptide. After three washes in TBS-Tween 20 0.05%, sections were incubated with the secondary antibodies diluted in the same buffer as the primary. Specificity of the secondary antibodies employed was tested by control experiments without primary antibody. Three more washes with TBS-Tween 20 0.05% and TBS were done prior the incubation of 5 min with Hoechst33258 (diluted 1/1000 in TBS) for nuclei visualization. Final washes in TBS were made before the mounting with Mowiol.
Sections were analyzed with a Nikon Eclipse 90i microscope equipped with conventional fluorescence: (1) DAPI filters (340-380nm excitation, 435-485nm emission), (2) FITC filters (465-495nm excitation, 515-555nm emission) and (3) G2-A filters (510-560nm excitation, 590 emission). Fluorescent images were captured with a high resolution (1280x1024 pixels) Nikon digital DXM1200F camera interfaced with the ACT-1 Nikon software. Image signal levels were adjusted using Adobe Photoshop software for a better visualization. Original images have been kept. Confocal images are a Z-stack of 5 photos (1µm/slice) made with an Olympus FluoView FV1000 (Olympus) microscope equipped with a UPLSAPO 60x NA: 1.35 objective. The following lasers were used: a 488nm laser (488nm excitation, 520nm emission) and a 559nm laser (559nm excitation, 618nm emission). Since the intensity of immunolabelling for the antibodies used could be due to many variables that cannot be individually quantified, this study does not attempt to quantify the relative amounts of labelled antigens. Colocalization of both antigens were measured with the FV10-ASW 1.7 software (Olympus) and are shown as average overlap ± standard deviation of seven different regions of interest for each image. When the overlap value is above 0.5 we consider both antigens colocalized.
Electrophysiology
The protocol used was adapted from [29] and was as follows: Brains from male Sprague-Dawley rats of 5 -9 weeks of age were rapidly extracted and placed in icecold Krebs buffer containing 124 mM NaCl, 3.5 mM KCl, 25 mM NaHCO 3 , 1.25 mM NaH 2 PO 4 , 1 mM CaCl 2 , 2 mM MgSO 4 , 10 mM glucose, 10 mM Hepes (pH 7.4) and oxygen saturated (95% O 2 /5% CO 2 ). Sagital corticostriatal slices (350 µm) were prepared from tissue blocks of the brain with a Vibratome (Leica, VT1000S) and maintained at least 2 h at room temperature in the Krebs buffer, containing 2 mM CaCl 2 . This medium was used for further recordings. A single slice was transferred to a recording chamber of an upright microscope (DMLFS, Leica). The slice was positioned under a nylon mesh and continuously superfused with oxygen saturated Krebs solution (flow rate 2 ml/min) maintained at 30-32ºC. Extracellular recordings were made using a glass micropipette (flame polished borosilicate capillary, inside diameter 0.58 mm, outside diameter 1 mm, Warner instruments; resistance 4-7 MΩ) with a wire (silver, 250 µm, A-M Systems) filled with perfusion medium and placed in the dorsal striatum. Afferent fibers were stimulated by delivering monophasic voltage pulses at a frequency of 0.05 Hz to a bipolar electrode (nickel chrome wire, bare diameter 50 µm, A-M Systems) connected to a multi-channel external stimulator (STG4, Multi channels systems) controlled by the software MC Stim (Multi channels systems). The stimulating electrode was placed in the corpus callosum, or in the striatum close to the border of the corpus callosum. Stimulation intensity ranged from 100-800 µA and 80-600 ms. The recording electrode was connected to a patch-clamp amplifier (Axopatch 200 B, Axon Instruments). Signals were digitized (Digidata 1200 Interface, Axon Instruments) and filtered at 2 kHz. Paired-pulse ratio was obtained by applying two stimuli with a 50 ms interval and calculated by dividing the second field potential amplitude by the amplitude of the first one (P2/P1). Data were collected by Win LTP (kind gift by Dr. W. Anderson, University of Bristol, UK). The amplitude of the field potential was used as a measure of synaptic transmission. After obtaining a stable baseline of at least 15 min, thioperamide was diluted in the Krebs solution and bath-applied. Field potential amplitudes were normalized to baseline amplitude. Each data point used for statistics was the mean of 8 consecutive field potentials. Results were pooled in Sigmaplot (Sigmaplot version 9) and represented as means (± SEM) of n= 5 animals.
Dopamine synthesis
Fresh rat brains were chilled immediately in modified Krebs-Ringerbicarbonate medium with the following composition: 120 mM NaCl, 0.8 mM KCl, 2.6 mM CaCl 2 
Results

H 3 R mRNA and protein expression in mesencephalic dopaminergic neurons.
In a previous study of H 3 R mRNA distribution in several brain regions [16] , no expression was apparent in the ventral tegmental area (VTA). In contrast in the present work we do describe H 3 R mRNA expression in the VTA using the same H 3 R cRNA probe for in situ hybridization as [16] . TSA amplification permitted to visualize H 3 R expression, particularly in dopaminergic neurons of the VTA identified by tyrosine hydroxylase mRNA (double in situ hybridization) and protein (double immunohistochemistry; Fig. 1A ). In agreement with Pillot et al [16] we confirm the presence of H 3 R mRNA and protein in substantia nigra pars compacta (SNc, ]-iodoproxyfan in the VTA as compared to the SNc. Thus, our results would agree with them after improvement of signal detection with TSA. Nevertheless, we controlled the specificity of the H 3 cRNA antisense probe used for in situ hybridization with the sense probe. In both our study and [16] a very low non-specific signal was detected in the VTA with the sense probe (Fig. S1) , but it was almost undetectable when compared with the specific signal of the antisense probe in the same conditions. We also controlled the specificity of the H 3 R antibodies used by comparing three different commercial antibodies (listed in Table 1 ) obtaining the same signal pattern. These antibodies where previously used in several studies [30, 31] . Moreover, the signal specificity of the Alpha Diagnostic anti-H3R (anti-H3Ral) antibody was completely abolished by preincubation with its blocking peptide (Fig.  S2) 
H 3 receptors inhibit dopamine synthesis
Striatal dopamine synthesis takes place in dopaminergic terminals arising from VTA and SNc. To search for H 3 R function in dopaminergic neurons we chose to determine dopamine synthesis in miniprism preparations of freshly dissected striatum. In the presence of different concentrations of the H 3 R agonist imetit, Fig. 2 ). This result was representative of three independent experiments, and it confirms a previous report with a different H 3 R agonist [9] . This suggests that H 3 R are functional inhibitory heteroreceptors in dopaminergic neurons.
H 3 R protein and mRNA expression in striatal neurons
Next we studied the presence of H 3 R mRNA (Fig. 3) and protein (Fig. 4) in striatal GABAergic projection neurons. Approximately half of H 3 R mRNA-positive neurons corresponded to each population of SP or PE-expressing GABAergic projection neurons (Fig. 3) . Almost all SP mRNA positive neurons expressed H 3 R mRNA (111 double-labelled of 126 SP positive neurons in accumbens and 115 of 133 in striatum). Similarly, almost all PE mRNA positive neurons expressed H 3 R mRNA (131 doublelabelled of 140 PE positive neurons in accumbens and 141 of 160 in striatum).
We also studied the colocalization of H 3 R protein and dopamine D 1 receptor immunoreactivities. Dopamine D 1 receptor immunoreactivity was more intense in neuronal somas, although it showed a pattern of expression suggesting terminal labelling. Using confocal imaging, we found H 3 R-D 1 R colocalization (Fig. 4) Fig. 5 . Cholinergic interneurons were identified by choline acetyltransferase (ChAT) immunoreactivity and by their big size.
H 3 R protein expression in glutamatergic endings. Effects on glutamate release.
The striatum receives a modulatory histaminergic input arising from the tuberomammillary nucleus of the hypothalamus [35] and three major synaptic inputs: the dopaminergic nigrostriatal pathway and the glutamatergic corticostriatal and thalamostriatal pathways [36] . These two glutamatergic inputs to striatal neurons can be easily distinguished on the basis of the vesicular transporter used for glutamate storage. Thalamic neurons express the vesicular glutamate transporter 2 while cortical neurons innervating the striatum express the vesicular glutamate transporter 1 (VGLUT1) [37] . As Fig. 6 To determine if H 3 receptors found on glutamatergic corticostriatal endings were functional, we recorded field potentials elicited by cortico-striatal stimulation. The application of H 3 R antagonist/inverse agonist thioperamide (100 nM) to fresh striatal brain slices induced an increase of field potential amplitude accompanied by a decrease of the paired-pulse ratio (Fig. 7) . This effect persisted during thioperamide application (30 min) and after washout (p<0.05 repeated-measures ANOVA), resulting in an enduring potentiation of field potential amplitude. A change in paired-pulse ratio is generally interpreted as a changed probability of neurotransmitter release reflecting a presynaptic action of the studied molecule. Thus the effects of 100 nM thioperamide clearly suggest a potentiation of corticostriatal glutamate release mediated by blockade of inhibitory H 3 R present in corticostriatal nerve endings.
H 3 R protein is not expressed in GFAPimmunoreactive astrocytes.
Astrocytes detected with an antibody against its specific marker, the glial fibrillary acidic protein (GFAP), are present in diverse brain areas including the neostriatum, the substantia nigra and the cortex [38] . We analyzed the possible presence of H 3 R in astrocytes and found no colocalization between H 3 R and GFAP proteins in medial prefrontal cortex, striatum or nucleus accumbens (Fig. 8) .
Overlap values obtained in these three brain regions were 0.29±0.03, 0.26±0.07 and 0.27±0.07 respectively, always below the preestablished threshold to detect colocalization.
Discussion
In the present work we describe the presence of histamine H 3 receptor expression in several neuronal types of rat basal ganglia: (1) nigrostriatal and mesolimbic dopaminergic neurons; (2) striatonigral and striatopallidal GABAergic neurons; (3) striatal cholinergic interneurons and (4) corticostriatal glutamatergic terminals. In addition, we show that H 3 receptors appear to be functional in dopaminergic and glutamatergic cells. Thus H 3 R are expressed in diverse cellular types and could mediate most histamine actions in these structures [39] .
We describe for the first time H 3 R mRNA presence in the VTA, which was not found in the study of brain H 3 R distribution by Pillot et al. [16] . The reason for this discrepancy could be due to the sensitivity of methodological procedures. In the Pillot et al. work a 33 P radioactive probe was used for a one-week exposition time, a relatively short and probably insufficient period for low levels of mRNA expression. In our case we used the same cRNA probe as Pillot et al. but we detected it with the potent TSA amplification system. This improvement revealed H 3 R mRNA expression in the VTA, specifically in dopaminergic cells. Pillot et al. also studied the brain distribution of H 3 R protein by binding with the H 3 R antagonist 125 I-iodoproxyfan. They found minimum binding in the VTA, much lower than in the dorsal striatum, Acb, cortex and substantia nigra (noteworthy weaker in SNc than in SNr, suggesting predominant H 3 R expression in striatonigral neurons as compared to nigrostriatal neurons). Using fluorescent immunohistochemistry we have confirmed H 3 R receptor presence in those areas (cortex, dorsal striatum, Acb, SNc and also VTA), but a comparison between regions was not attempted due to the difficulties of fluorescence quantification. Although H 3 R expression can be lower in the VTA and SNc than in other regions, we show it is clearly present in dopaminergic neurons characterized both by tyrosine hydroxylase immunoreactivity and mRNA expression. Furthermore, H 3 R stimulation decreased dopamine synthesis in striatal tissue ( Fig. 2 and [9] ), as expected according to the typically inhibitory role of H 3 R in other cells [5, 6] . Although dopamine release could also be modulated by H 3 R, this effect was more clearly described in the prefrontal cortex than in the striatum [40, 41] . In the Acb shell H 3 R ligands modulate methamphetamine-stimulated dopamine release, but fail to modulate nonstimulated release [42] . Thus despite low expression levels, we can conclude that functional inhibitory H 3 R are present in dopaminergic neurons projecting to the prefrontal cortex, dorsal striatum and Acb.
Colocalization of PE or SP mRNA with H 3 R mRNA in the striatum and nucleus accumbens (Fig. 3) confirms H 3 R expression in all GABAergic medium spiny projection neurons [43, 44] . In striatonigral neurons, H 3 R are functional taking into account that: 1) H 3 R stimulation reduces dopamine D 1 receptor-dependent GABA release [11] ; 2) H 3 R stimulation inhibits dopamine D 1 receptor-stimulated cAMP accumulation [45] , and 3) D 1 R -H 3 R receptor heteromers stimulate MAP kinase specifically in these cells [44] . In striatopallidal neurons, H 3 R presence agrees with 1) a previous report of H 3 R mRNA in PE positive neurons [46] and 2) colocalization of D 2 and H 3 immunolabelling [44] . However, proof of H 3 R functionality in striatopallidal neurons is still insufficient. D 2 and H 3 receptors can interact forming heteromers in living cells in vitro, and locomotor tests suggest they could also interact in vivo [46, 47] , but it is still uncertain whether this interaction actually occurs in striatal neurons [48] . Recently, Ellender et al. (2011) [39] reported that histamine modulates lateral inhibition between collaterals of striatal medium spiny neurons, although the authors did not test H 3 R involvement in this effect.
Currently, the existence of a population of medium spiny neurons which coexpress D 1 and D 2 receptors is accepted [21, 49] . In addition, all neurons expressing D 1 receptors appear to contain low levels of D 2 receptors and vice versa [20] . In the ventral striatum a subset of D 1 and D 2 receptor-expressing neurons coexpress dopamine D 3 receptors [50] . Additional populations of striatal efferent neurons coexpress (1) D 4 and D 5 receptors [51] , (2) D 1 receptors, SP and also PE, projecting to the SNc [52] , and (3) D 1 receptors and neurokinin B (but not SP or PE), projecting to the substantia innominata [19] . Thus, separation of neuronal populations can not be performed based on D 1 receptor labelling. In this paper all H 3 R protein immunoreactive neurons in the studied areas showed D 1 protein immunoreactivity (Fig. 4) . This might imply H 3 R expression in neurons where D 1 and D 2 receptors are colocalized, but we did not attempt to demonstrate this by triple labelling. The specificity of the dopamine D 1 receptor antibody used here was described by Narushima et al. [53] . In Narushima's paper, partial colocalization of D 1 (Fig. 4) . In contrast, glutamatergic inputs are described to express only the D 2 -like class of dopamine receptors [54] . Similarly, the D 1 R -H 3 R protein colocalization found in the medial prefrontal cortex could be due to the H 3 R presence in the D 1 R-expressing GABAergic interneurons of the cortex.
It is well known that excitatory corticostriatal afferents to the striatum innervate both populations of mediumsized spiny GABAergic projection neurons [55] . We found H 3 R immunoreactivity in corticostriatal glutamatergic inputs to the striatum (Fig. 6) . The colocalization of H 3 R and VGLUT1 agrees with functional studies showing that 1) the H 3 R inverse agonist thioperamide at 100 nM changed the paired-pulse ratio of corticostriatal synapses (Fig. 7A) , an index of altered probability of presynaptic neurotransmitter (glutamate) release [56] ; 2) H 3 R mediate the synaptic depression induced by histamine in corticostriatal inputs [57, 39] . Conversely, the H 3 R inverse agonist thioperamide relieves the repression exerted by presynaptic H 3 R on glutamatergic terminals, allowing an increased release of presynaptic glutamate that potentiates field potentials (Fig. 7B) . The concentration of thioperamide we used in the present study (100 nM) should fully occupy H 3 R, although it is much lower than that used in Doreulee and Ellender studies (10 M) to block histamineinduced synaptic depression. We must note that bath application of 10 M thioperamide alone did not affect field potential amplitude or paired pulse ratios (data confirmed by us, in agreement with previous studies [57, 39] ). We do not have an explanation for thioperamide concentration-dependent effects, but we could speculate that higher concentrations may have effects on an additional subset of receptors (and see [13] ). Independently of that, Ellender et al. (2011) [39] suggested that H 3 R mediate histamine depression of corticostriatal synapses and favor thalamostriatal transmission, but the presence of H 3 R in thalamostriatal terminals has not yet been demonstrated. H 3 R activation in striatal synaptosomes inhibits glutamate release [10] , but striatal synaptosomes may be formed from cortical, thalamic or additional inputs. Taken together, we can conclude that functionally inhibitory H 3 R are present in corticostriatal terminals, limiting glutamate release.
Our results show that striatal cholinergic neurons present histamine H 3 receptor immunoreactivity. Due to the low number of striatal cholinergic interneurons, we were unable to show direct effects of H 3 R ligands specifically in these cells, but there are numerous studies where H 3 R modulation of acetylcholine release has been observed in diverse brain regions: (1) in the amygdala H 3 R agonists increased acetylcholine release [58] ; (2) in the cortex H 3 R agonists decreased acetylcholine release [32, 33] ; (3) in the hippocampus H 3 R antagonists increased acetylcholine release [59] ; (4) in the ventral striatum of freely moving rats acetylcholine release was stimulated by both H 3 R agonists and inverse agonists by acting at H 3 receptors putatively located in different populations of neurons, although no evidence was obtained of direct effects of H 3 ligands on cholinergic neurons [34] . Thus, the possibility that H 3 receptors in striatal cholinergic interneurons are functional is still uncertain. Although we did not find H 3 R presence in GFAP-immunoreactive astrocytes in the medial prefrontal cortex, striatum or nucleus accumbens, this colocalization was recently shown at the caudal spinal trigeminal nucleus of nonhuman primates [60] . Thus H 3 R presence in astrocytes could be limited to some areas. In cultured astrocytes histamine seems to act through H 1 receptors to induce inositol phosphate accumulation [61] and calcium entry [62] but we have found no literature evidence of H 3 receptor-mediated effects in astrocytes.
Due to the presence of functional H 3 R in such different cellular types, what role should these receptors have in striatal function? Regarding locomotion, it has been shown that histamine action on H 3 R elicits a fast hypokinetic effect, and afterwards histamine would activate H 1 receptors to elicit hyperactivity [23] . The hypokinetic effect could be explained by a transient decrease of dopamine neurotransmission provoked by H 3 R stimulation. However H 3 R KO mice exhibit lower locomotion than wild-type mice [24] , a finding that is hard to reconcile with the H 3 -mediated hypokinetic effect and with the observation that H 3 antagonists do not change locomotor activity. An interpretation given by these authors is that the absence of H 3 inhibitory autoreceptors in histamine neurons of KO mice could favor histamine release, which could decrease neuronal histamine levels, which in turn could decrease activation of H 1 receptors [24] . Developmental adaptations in H 3 R KO mice are difficult to interpret given the varied cellular types expressing H 3 R in the basal ganglia.
Several H 3 R agonists decrease Ldopa and apomorphine-induced turning behavior in 6-hydroxydopamine lesioned rats [26, 63] as well as L-dopa-induced chorea in MPTP-lesioned monkeys [28] . These effects could be due to H 3 R-mediated decrease of GABA release in the SNr [64] (but see [65] ). In reserpinized mice, H 3 receptor stimulation decreases locomotion induced by dopaminergic agonists [47] . These effects should be independent of H 3 R expression in dopaminergic neurons. In brains from Parkinson disease patients a strong H 3 R binding was found in the SNr [66] . Thus, it is likely that H 3 R in the GABAergic direct pathway could account for the majority of the effects of H 3 R agonists in models of Parkinson's disease. H 3 R and D 1 R in these neurons have opposite effects [11, 44] and dopaminergic lesions may sensitize them [66, 45] .
The effects of H 3 R antagonists / inverse agonists in the basal ganglia can be more difficult to interpret. H 3 R inverse agonists would (1) stimulate histamine release, which may lead to H 1 -mediated effects such as hyperlocomotion [23, 67] and H 2 -mediated depolarization of medium spiny neurons [39] ; (2) facilitate glutamate release from corticostriatal terminals (Fig.  7) ; and (3) stimulate cortical dopamine release [40] . In reserpinized mice, the H 3 R antagonists / inverse agonist thioperamide potentiates locomotion elicited by dopaminergic agonists [47] . However, antagonism of H 3 R in striatonigral neurons could also block D 1 -H 3 receptor heteromers [44] , whose involvement in locomotion is uncertain, but could contribute to dopamine-mediated effects. D 1 -H 3 receptor heteromers work as processors integrating dopaminergic and histaminergic signals that can be blocked by antagonists of either receptor protomer composing the heteromer [44] . According to H 3 R expression in several neuronal types of the basal ganglia, further studies would be needed to determine whether H 3 R ligands could be therapeutically useful in Parkinson's disease or related movement disorders [68] . Similarly, further studies of H 3 R antagonists / inverse agonists would be advisable in models of other disorders where the basal ganglia play a central role such as attention-deficit hyperactivity disorder, schizophrenia and alcohol abuse [25, 26] . The fact that each neuronal pathway involved expresses H 3 R difficults prediction of the predominant functional effects of H 3 R antagonists / inverse agonists. We expect these ligands would favor histamine actions on other histamine receptor subtypes, but their effects on glutamatergic and dopaminergic neurotransmissions must also be considered. were evoked by either single (A) or paired (B) stimuli of cortico-striatal afferents. As shown in A, thioperamide (100nM, 30min) induced a slow-onset increase in fEPSP amplitude which continued up to 20min after washout. On the graph, data are means ± SEM (n = 3-5 slices obtained from different animals) of fEPSP amplitudes normalized to their respective baseline activity. In B, pooled paired-pulse facilitation ratio measured 5 min before and 20 min after thioperamide washout are shown. Paired-pulse facilitation was obtained by delivering two stimuli with a 50ms interval. Paired-pulse facilitation ratio was further calculated by dividing the second peak amplitude (P2) by the first one (P1). On the graph, data are expressed as averages of paired-pulse ratios (P2/P1) ± SEM obtained from 5 individual experiments where each determination is the mean of 8 consecutive fEPSP. The decrease of the paired-pulse ratio suggests that presynaptic H 3 R alter the probability of neurotransmitter release. Representative electrophysiological traces are shown above each graph. They were extracted during baseline activity and 20min after thioperamide washout when signals reached a stable amplitude. In both A and B changes were statistically significant (* p<0.05 versus controls, repeated measures ANOVA). Table 1 for antibody details. Scale bar 35µm.
